LONDON--(BUSINESS WIRE)--Sept. 14, 2006--NuCana Ltd., an emerging biopharmaceutical company focused on the in-licensing and development of innovative therapies, targeting cancer and autoimmune disorders, has announced a high profile research and development agreement with Cardiff ProTides Ltd - a drug discovery company spun out from the Welsh School of Pharmacy, Cardiff University which applies its unique ProTide technology to improve the profile and activity of existing anti-cancer agents. The resulting novel drugs are new chemical entities based on the existing anti-cancer agents.
